IgA pemphigus accompanying multiple myeloma has disappeared following the treatment with bortezomib (Velcade), cyclophosphamide and dexamethasone. Case study and literature review

Česká verzia

Authors: Z. Adam ¹; J. Feit ²; M. Krejčí ¹; L. Pour ¹; V. Vašků ³; Z. Čermáková ⁴; J. Mayer ¹; R. Hájek ¹
Authors place of work: Interní hematoonkologická klinika Lékařské fakulty MU a FN Brno, pracoviště Bohunice, přednosta prof. MU Dr. Jiří Vorlíček, CSc. ¹; Ústav patologie Lékařské fakulty MU a FN Brno, pracoviště Bohunice, přednosta doc. MU Dr. Josef Feit, CSc. ²; I. dermatovenerologická klinika Lékařské fakulty MU a FN u sv. Anny Brno, přednosta doc. MU Dr. Vladimír Vašků, CSc. ³; Oddělení klinické biochemie Fakultní nemocnice Brno, pracoviště Bohunice, přednosta doc. MU Dr. Milan Dastych, CSc. ⁴
Published in the journal: Vnitř Lék 2009; 55(10): 981-990
Category: Case Reports

Summary

IgA pemphigus, resembling subcorneal pustulous dermatosis, represents a rare complication of IgA type monoclonal gammopathy. The patient dates the onset of initial symptoms of vesicular‑ bullous disease to 1990. She was first examined at our clinic in 2001 with the following conclusion “type IgA monoclonal gammopathy of unknown significance”. The first immunosuppressive treatment of vesicular- bullous disorder was administered in 2003 (dexamethasone 20 mg on days 1– 4 and 15– 18 in monthly cycles + daily cyclophosphamide 50 mg). Cyclophosphamide was administered for 6 months in total and dexamethasone for further 3 months. During the treatment, intensity of the skin disorder ameliorated and monoclonal IgA levels decreased to non‑detectable levels. Nevertheless, skin symptoms recurred immediately after dexamethasone treatment in its original intensity was terminated, even though the concentration of monoclonal immunoglobulin IgA remained below the sensitivity of quantitative detection for further 6 months (positive immunofixation only). Six rituximab 600 mg infusions were administered in a weekly interval after stopping cyclophosphamide and dexamethasone to prevent early recurrence of skin symptoms but this treatment was without any lasting effect. Transformation into multiple myeloma was identified in 2007. First line treatment (cyclophosphamide, adriamycin and dexamethasone – CAD) remained without any haematological or dermatological treatment response. Second line treatment (thalidomide, cyclophosphamide and dexamethasone – CTD) brought about significant deterioration of skin symptoms up to the clinical picture of erythrodermia. Third line treatment (bortezomib 1.3 mg/ sqm i.v. on days 1, 4, 8 and 15, cyclophosphamide 50 mg daily and dexamethasone 20 mg on days 1– 4 and 15– 18 in 28-day cycles – VCD) resulted in rapid decline in monoclonal immunoglobulin IgA concentrations immediately following the first cycle and to negative immunofixation after 5 cycles. In total, six VCD cycles were administered. The patient has had no skin symptoms from the third cycle of this treatment and complete skin and haematological remission has been maintained for 12 months after completion of bortezomib- containing treatment. Combined treatment containing bortezomib has proven useful in the treatment of IgA pemphigus accompanying monoclonal gammopathy of uncertain significance transformed into multiple myeloma.

Key words:
IgA pemphigus – subcorneal pustulous dermatosis – bortezomib – rituximab – monoclonal gammopathy of uncertain significance – multiple myeloma

Zdroje

1. Tichý M. Laboratorní analýza monoklonálních imunoglobulinů (paraproteinů). Český Těšín: Finidr 1997.

2. Tichý M. Paraproteinemie nejasného původu. Klin Biochem Metabol 1998; 6: 172– 175.

3. Ščudla V, Bačovský J, Indrák K et al. Výsledky léčby a změny prognózy nemocných s mnohočetným myelomem v období předchozích 40 let v oblasti střední a severní Moravy. Rozbor 562 nemocných. Vnitř Lék 2002; 48: 707– 717.

4. Špička I, Hájek R, Vytřasová M et al. Inhibitor proteazomu – bortezomib (Velcade) – v léčbě refrakterního mnohočetného myelomu. První zkušenosti v České republice. Čas Lék Čes 2005; 144: 636– 640.

5. Tichý M, Maisnar V. Laboratorní průkaz monoklonálních imunoglobulinů. Vnitř Lék 2006; 52 (Suppl 2): 41– 45.

6. Tichý M, Řeháček V, Maisnar V et al. Monoklonální gamapatie v souboru 1 683 dárců plazmy. Čas Lék Čes 2004; 143: 401– 404.

7. Schnitzler L, Verret JL, Schubert B et al. Subcorneal pustulosis (Sneddon- Wilkinson disease) with acantholysis and IgA myeloma (13‑year follow‑up). Ann Dermatol Venereol 1977; 104: 170– 172.

8. Varigos GA. Subcorneal pustulosis with IgA abnormalities in serum and small bowel mucosa: case report. Australas J Dermatol 1979; 20: 75– 77.

9. Wallach E. Intraepidermal IgA pustulosis. J Am Acad Dermatol 1992; 27: 993– 1000.

10. Hodak E, David M, Ingber A et al. The clinical and histopathological spectrum of IgA pemphigus report of 2 cases. Clin Exp Dermatol 1990; 15: 433– 437.

11. Teraki Y, Amagai N, Hashimoto T et al. Intercellular IgA dermatosis of a childhood. Selective deposition of monomer IgA1 in the intercellular space of the epidermis. Art Dermatol 1991; 127: 221– 224.

12. Iwatsuki K, Hashimoto T, Ebihara T et al. Intercellular IgA vesiculo pustular dermatosis and related disorders: diversity of anti of anti IgA antiintecellular antoantibodies. Eur J Dermatol 1993; 3: 7– 11.

13. Cheng S, Edmonds E, Ben‑ Gashir M et al. Subcorneal pustular dermatosis: 50 years on. Clin Exp Dermatol 2008; 33: 229– 233.

14. Ongenae KC, Temmerman LJ, Vermander F et al. Intercellular IgA dermatosis. Eur J Dermatol 1999; 9: 85– 94.

15. Harati A, Brockmeyer NH, Altmeyer Pet al. Skin disorders in association with monoclonal gammopathies. Eur J Med Res 2005; 10: 93– 104.

16. Birnkrant MJ, Papadopoulos AJ, Schwartz RA et al. Pyoderma gangrenosum, acne conglobata and IgA gammopathy. Int J Dermatol 2003; 42: 213– 216.

17. Rongioletti F, Patterson JW, Rebora A.The histological and pathogenetic spectrum of cutaneous diseases in monoclonal gammopathies. J Cutan Pathol 2008; 35: 705– 721.

18. Aste N, Fumo G, Pinna AL et al. IgA pemphigus of the subcorneal pustular dermatosis type associated with monoclonal IgA gammopathy. J Eur Acad Dermatol Venereol 2003; 17: 725– 727.

19. Sriprakash K, Yong‑Gee S. Multiple minute digitate hyperkeratoses associated with paraproteinaemia. Australas J Dermatol 2008; 49: 233– 236.

20. Bernard P, Amici JM, Bedane C et al. Intra‑ epidermal neutrophilic IgA dermatosis associated with IgA myeloma. Ann Dermatol Venereol 1990; 117: 890– 892.

21. Bölcskei L, Husz S, Hunyadi J et al. Subcorneal pustular dermatosis and IgA multiple myeloma. J Dermatol 1992; 19: 626– 628.

22. Bowden JR, Scully C, Eveson JW et al. Multiple myeloma and bullous lichenoid lesions: an unusual association. Oral Surg Oral Med Oral Pathol 1990; 70: 587– 589.

23. Miyagawa S, Hashimoto T, Ohno H et al. Atypical pemphigus associated with monoclonal IgA gammopathy. J Am Acad Dermatol 1995; 32: 352– 357.

24. Niimi Y, Kawana S, Kusunoki T. IgA pemhigus. A case report and its characteristics clinical features compared with subcorneal pustular dermatosis. J Am Acad Dermatol 2000; 43: 546– 549.

25. Guana AL, Cohen PR. Transient acantholytic dermatosis in oncology patients. J Clin Oncol 1994; 12: 1703– 1709.

26. Ahmad K, Ramsay B. Pyoderma gangrenosum associated with subcorneal pustular dermatosis and IgA myeloma. Clin Exp Dermatol 2009; 34: 46– 48.

27. Andersen BL. Pyoderma gangrenosum associated with transient acantholytic dermatosis (pemphigus erythematosus‑like) and paraproteinemia. Acta Derm Venereol 1981; 61: 77– 79.

28. Horton JJ, Trounce JR, MacDonald DM. Bullous pyoderma gangrenosum and multiple myeloma. Br J Dermatol 1984; 111: 227– 230.

29. Ray R, Kanwar AJ, Ravichandran P et al. Pemphigus vulgaris with cryoglobulinemia and cold agglutinin disease. J Assoc Physicians India 1994; 42: 420– 422.

30. Kurokawa M, Koketsu H, Oda Y et al. A case of pemphigus vulgaris accompanied by multiple myeloma. Int J Dermatol 2005; 44: 873– 875.

31. Zhu X, Zhang B. Paraneoplastic pemphigus. J Dermatol 2007; 34: 503– 511.

32. Stiefelhagen P. Recurrent blood blisters on hands and face. The skin is a mirror of the bone marrow. MMW Fortschr Med 2007; 149: 19.

33. Stone MS, Lyckholm LJ. Pyoderma gangrenosum and subcorneal pustular dermatosis. Clues to underlying imunoglobulin a myeloma. Am J Med 1996; 100: 663– 664.

34. Stoopler ET, Alawi F, Laudenbach JM et al. Bullous amyloidosis of the oral cavity: a rare clinical presentation and review. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006; 101: 734– 740.

35. Lautenschlager S, Itin PH, Hirsbrunner Pet al. Subcorneal pustular dermatosis at the injection site of recombinant human granulocyte‑ macrophage colony‑ stimulating factor in a patient with IgA myeloma. J Am Acad Dermatol 1994; 30: 787– 789.

36. Kirsner RS, Anhalt GJ, Kerdel FA. Treatment with alpha interferon associated with the development of paraneoplastic pemphigus. Br J Dermatol 1995; 132: 474– 478.

37. Dal Tio R, Di Vito F, Salvi F. Subcorneal pustular dermatosis and IgA myeloma. Dermatologica 1985; 170: 240– 243.

38. Engineer L, Dow EC, Braverman IM et al. Epidermolysis bullosa acquisita and multiple myeloma. J Am Acad Dermatol 2002; 47: 943– 946.

39. Lutz ME, Daoud MS, McEvoy MT et al. Subcorneal pustular dermatosis: a clinical study of ten patients. Cutis 1998; 61: 203– 208.

40. Roger H, Thevenet JP, Souteyrand P. Subcorneal pustular dermatosis associated with rheumatoid arthritis and raised IgA. Simultaneous remission of skin and joint involvement with dapsone treatment. Ann Rheum Dis 1990; 49: 190– 191.

41. Todd DJ, Bingham EA, Walsh M et al. Subcorneal pustular dermatosis and IgA paraproteinemia: response to etretinate and PUVA. Br J Hematol 1991; 125: 387– 389.

42. Takata M, Inaoki M, Shodo M et al. Subcorneal pustular dermatosis associated with IgA myeloma and intraepidermal IgA deposits. Dermatology 1994; 189 (Suppl 1): 111– 114.

43. Atukorala DN, Joshi RK, Abanmi A et al. Subcorneal pustular dermatosis and IgA myeloma. Dermatology 1993; 187: 124– 126.

44. Vaccaro M, Cannavò SP, Guarneri B. Subcorneal pustular dermatosis and IgA lambda myeloma: a uncommon association but probably not coincidental. Eur J Dermatol 1999; 9: 644– 646.

45. Kasha EE jr, Epinette WW. Subcorneal puslutal dermatosis (Sneddon Wilkinson disease in association with monoclonal IgA gammopathy. Report and review of the literature. J Am Acad Dermatol 1988; 19: 854– 858.

46. Perera GK, Devereux S, Mufti G et al. PNP with Waldenström’s macroglobulinaemia. Clin Exp Dermatol 2005; 30: 27– 29.

47. Petropoulou H, Politis G, Panagakis P et al. Immunoglobulin A pemphigus associated with immunoglobulin A gammopathy and lung cancer. J Dermatol 2008; 35: 341– 345.

48. Vincendeau P, Claudy A, Thivolet J et al. Bullous dermatosis and myeloma. Monoclonal anticytoplasmic antibody activity. Arch Dermatol 1980; 116: 681– 682.

49. Wang XD, Shen H, Liu ZH. Diffuse haemorrhagic bullous amyloidosis with multiple myeloma. Clin Exp Dermatol 2008; 33: 94– 96.

50. Wong DA, Hunt MJ, Stapleton K. IgA multiple myeloma presenting as an acquired bullous disorder. Australas J Dermatol 1999; 40: 31– 34.

51. Ochiai T, Morishima T, Hao T et al. Bullous amyloidosis: the mechanism of blister formation revealed by electron microscopy. J Cutan Pathol 2001; 28: 407– 411.

52. Ohno H, Miyagawa S, Hashimoto T et al. Atypical pemphigus with concomitant IgG and IgA anti‑intercellular autoantibodies associated with monoclonal IgA gammopathy. Dermatology 1994; 189 (Suppl 1):115– 116.

53. Radfar L, Fatahzadeh M, Shahamat Y et al Paraneoplastic epidermolysis bullosa acquisita associated with multiple myeloma. Spec Care Dentist 2006; 26: 159– 163.

54. Becker LR, Bastian BC, Wesselmann Uet al. Paraneoplastic pemphigus treated with dexamethasone/ cyclophosphamide pulse therapy. Eur J Dermatol 1998; 8: 551– 553.

55. Meijs M, Mekkes J, van Noesel C et al. Paraneoplastic pemphigus associated with follicular dendritic cell sarcoma without Castleman’s disease; treatment with rituximab. Int J Dermatol 2008; 47: 632– 634.

56. Schadlow MB, Anhalt GJ, Sinha AA. Using rituximab (anti‑CD20 antibody) in a patient with paraneoplastic pemphigus. J Drugs Dermatol 2003; 2: 564– 567.

57. Fernando SL, O‘Connor KS. Treatment of severe pemphigus foliaceus with rituximab. Med J Aust 2008; 189: 289– 290.

58. Jessop S, Khumalo NP. Pemphigus: a treatment update. Am J Clin Dermatol 2008; 9: 147– 154.

59. Schierl M, Foedinger D, Geissler K et al. Paraneoplastic pemphigus despite treatment with rituximab, fludarabine and cyclophosphamide in chronic lymphocytic leukemia. Eur J Dermatol 2008; 18: 717– 718.

60. Schmidt E, Bröcker EB, Goebeler M. Rituximab in treatment‑resistant autoimmune blistering skin disorders. Clin Rev Allergy Immunol 2008; 34: 56– 64.

61. Sorce M, Aricò M, Bongiorno MR. Rituximab in refractory pemphigus vulgaris. Dermatol Ther 2008; 21 (Suppl 1): S6– S9.

62. Zambruno G, Borradori L. Rituximab immunotherapy in pemphigus: therapeutic effects beyond B‑ cell depletion. J Invest Dermatol 2008; 128: 2745– 2747.

63. Bölcskei L, Husz S, Hunyadi J et al. Subcorneal pustular dermatosis and IgA multiple myeloma. J Dermatol 1992; 19: 626– 628.